There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2


IL-2 Molecule Information

Target Synonym:TCGF;INN=Aldesleukin;Interleukin-2;T-cell growth factor;IL2;IL-2
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:30
Lastest Research Phase:Approved

IL-2 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
IL2-H52H8 Human Human IL-2 Protein, His Tag
IL2-H82E4 Human Biotinylated Human IL-2 Protein, His,Avitag™
IL2-H82F3 Human Biotinylated Human IL-2 Protein, Fc,Avitag™
IL2-H4113 Human Human IL-2 Protein, Tag Free

IL-2 Part of Bioactivity data

IL2-H4113-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-2, Tag Free (Cat. No. IL2-H4113) stimulates proliferation of CTLL-2 cells. The ED50 for this effect is 0.284-0.355 ng/ml (Routinely tested).


Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody, can bind IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).


Loaded Biotinylated Human IL-2, His,Avitag (Cat. No. IL2-H82E4) on SA Biosensor, can bind Human IL-2 R beta, His Tag (SPR verified) (Cat. No. CD2-H5221) with an affinity constant of 1.3 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

IL-2 Molecule Synonym Name

IL2,TCGF,lymphokine,Interleukin 2

IL-2 Molecule Background

Interleukin-2 (IL-2) is an interleukin, a type of cytokine immune system signaling molecule, which is a leukocytotrophic hormone that is instrumental in the body's natural response to microbial infection and in discriminating between foreign (non-self) and self. IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the cells that are responsible for immunity. Mature human IL-2 shares 56% and 66% aa sequence identity with mouse and rat IL-2, respectively. Human and mouse IL-2 exhibit crossspecies activity. The receptor for IL-2 consists of three subunits that are present on the cell surface in varying preformed complexes. IL-2 is also necessary during T cell development in the thymus for the maturation of a unique subset of T cells that are termed regulatory T cells (T-regs). After exiting from the thymus, T-Regs function to prevent other T cells from recognizing and reacting against "self antigens", which could result in "autoimmunity". T-Regs do so by preventing the responding cells from producing IL-2. Thus, IL-2 is required to discriminate between self and non-self, another one of the unique characteristics of the immune system.

IL-2 References

IL-2 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Recombinant Human Interleukin-2 Injection (Beijing Four Rings Biopharmaceutical) Approved Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin-2 Injection cfda Renal carcinoma, Melanoma 2016-04-29 Renal carcinoma, Melanoma Details
Thalidomide NSC-527179; NSC-66847; K-17,NSC527179; NSC66847; K17,NSC 527179; NSC 66847; K 17 Approved Celgene THALOMID fda Erythema nodosum leprosum (ENL), Multiple myeloma (MM) CELGENE 1998-07-16 Erythema nodosum leprosum (ENL), Multiple myeloma (MM) Details

IL-2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VPM-4001 VPM-4001; VPM-4-001,VPM 4001; VPM 4 001,VPM4001 Phase Ⅱ Memorial Sloan-Kettering Cancer Center, Vakzine Projekt Management Prostate cancer Details
Interleukin-2 (Amgen) Phase Ⅱ Amgen Cancer Details
AdCAIL-2 (McMaster University) Phase Ⅰ McMaster University Breast cancer, Melanoma Details
Vector-based gene therapy (National Institutes of Health) Phase Ⅰ National Institutes of Health Colon cancer, Renal cell carcinoma, Melanoma Details
Interleukin-2 gene therapy (St Jude Children's Research Hospital) Phase Ⅰ St Jude Children's Research Hospital, National Cancer Institute Neuroblastoma Details
Interleukin-2 gene therapy (UCLA) Phase Ⅰ University of California at Los Angeles Colon cancer, Prostate cancer, Melanoma Details
Albumin-interleukin-2 Phase Ⅰ CSL Behring, Human Genome Sciences Cancer Details
Pegylated interleukin-2 (Chiron) Phase Ⅱ Chiron HIV infection, Squamous cell carcinoma of head and neck cancer (SCCHN), Metastatic cancer Details
T20K T-20K Phase Ⅰ Cyxone Multiple sclerosis (MS) Details
Tucotuzumab celmoleukin EMD-273066; huKS-IL2; KS-IL2 Phase Ⅱ EMD Lexigen, Merck Serono Small cell lung cancer (SCLC), Ovarian cancer Details
Gene therapy for renal cell carcinoma (Shire) Phase Ⅰ Shire Renal carcinoma Details
Human interleukin-2 biosimilar (Amoytop Biotech/BioGeneric Pharma) rHuIL-2 Phase Not Specified BioGeneric, Xiamen Amoytop Biotech Metastatic renal cell carcinoma, Melanoma Details
Darleukin/fibromun L19-IL-2/ L19-TNF-α Phase Ⅲ Philogen Melanoma Details
Interleukin-2 (Roussel Uclaf) U-49637; RU-49637; IL-2 (Roussel Uclaf) Phase Ⅲ Sanofi, Transgene Cancer Details
TG-1031 TG-1031; pTG-1031 Phase Ⅱ Transgene Prostate cancer, Breast cancer Details
S-95007 S-95007 Phase Ⅱ Servier Immune-inflammatory diseases, Immunological disorders Details
Interleukin-2 controlled release (Avadel Pharmaceuticals) Phase Ⅱ Avadel Pharmaceuticals Renal carcinoma Details
ITI-1000 ITI-1000 Phase Ⅱ Immunomic Therapeutics, Duke University Medical Center Glioblastoma Details
HBAI-20 HBAI-20; HBAI-20-CyTuVax Phase Ⅱ CyTuVax HBV infection Details
IL-2 gene therapy (Imperial Cancer Research Technology) Phase Ⅰ Cancer Research UK Melanoma Details
Bifikafusp alfa L19-IL-2 Phase Ⅲ Philogen, Bayer Diffuse large B cell lymphoma, Atherosclerosis, Renal carcinoma, Head and neck cancer, Pancreatic cancer, Melanoma Details
TG-4010 TG-4010; VV-MUC-IL2 Phase Ⅲ Transgene Non small cell lung cancer (NSCLC) Details
Whole cell vaccine (Oncbiomune) Phase Not Specified Oncbiomune Breast cancer Details
PMI-001 PMI-001,PMI 001,PMI001 Phase Ⅲ Phytomedics Lupus vulgaris, Psoriasis, Multiple sclerosis (MS), Rheumatoid arthritis (RA) Details
Interleukin-2 gene therapy (Institute of Cancer Research UK) Phase Ⅰ Institute of Cancer Research Melanoma Details
Autologous tumor cell vaccine (NCI) Phase Ⅱ H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute, Chiron Renal carcinoma Details
AC-9401 AC-9401 Phase Ⅱ AntiCancer Inc Cancer Details
ALVAC-hIL-2 ALVAC-IL-2; ALVAC-hIL-2; vCP277,ALVAC-IL 2; ALVAC-hIL 2,ALVAC-IL2; ALVAC-hIL2 Phase Ⅱ Sanofi Pasteur Cancer Details
Interleukin-2 gene therapy (Valentis) VLTS-587 Phase Ⅱ Valentis Lung cancer, Head and neck cancer, Melanoma Details
DAB-486-IL-2 Phase Ⅱ Seragen, Lilly Type 1 diabetes, HIV infection, Lymphoma, Rheumatoid arthritis (RA), Kaposi's sarcoma Details

This web search service is supported by Google Inc.